British cancer drug developer Ellipses Pharma explores London Stock Exchange listing
Ellipses Pharma targets early 2027 London Stock Exchange listing via reverse takeover of Wolfram Resources to fund cancer drug development.

Photo: gren / Wikimedia Commons (Public Domain)
The London based oncology company is considering a reverse takeover of listed investment vehicle Wolfram Resources, with a potential flotation targeted for early 2027.
British cancer drug developer Ellipses Pharma is exploring a listing on the London Stock Exchange through a proposed reverse takeover, in a move intended to provide greater access to investment capital and support the development of new cancer treatments.
The London based company announced on 18 November that it had signed a nonbinding memorandum of understanding with Wolfram Resources Plc, a special purpose acquisition company already listed on the London Stock Exchange's Main Market.
Under the proposed arrangement, Wolfram would acquire the entire issued share capital of Ellipses, with the enlarged business subsequently seeking admission to the Equity Shares (Commercial Companies) category of the Main Market.
The transaction remains subject to due diligence, negotiations and the agreement of final terms, with completion provisionally targeted for early 2027.
Supporting the development of cancer treatments
Founded in 2017, Ellipses Pharma specialises in identifying and advancing promising cancer treatments through clinical development.
The company operates internationally, with clinical trial sites across the United States, Europe and the Asia Pacific region.
Its portfolio includes several programmes currently undergoing clinical investigation.
Among them is EP0031, also known as lunbotinib, a selective RET inhibitor being developed for patients with non small cell lung cancer involving alterations in the RET gene.
The treatment is currently in Phase 2 development through a partnership with Kelun Biotech.
Another significant programme is EP0062, or vosilasarm, an oral selective androgen receptor modulator undergoing Phase 2 development for patients with oestrogen receptor positive, HER2 negative breast cancer.
Both treatments remain investigational, with further clinical development required to establish their safety and effectiveness.
The proposed listing would provide Ellipses with a potential route to raise additional funding as it progresses these programmes.
A potential boost for British life sciences
Professor Sir Chris Evans OBE, founder and chairman of Ellipses Pharma, said the company's progress in clinical development had created an opportunity to pursue a public listing.
"Our company has been focused resolutely on the development of promising drug candidates and the progress made with our pipeline, including encouraging results from our clinical trials for both EP0031 and EP0062, which indicates that this is now the optimal time to move towards a public listing."
He also described the potential flotation as a positive development for Britain's life sciences industry, which continues to depend on access to investment to translate scientific research into commercially available treatments.
The proposed transaction comes as the UK seeks to maintain its position as an international centre for pharmaceutical research, biotechnology and medical innovation.
For companies developing new cancer therapies, access to long term capital is particularly important because clinical trials can require substantial investment over several years before a treatment reaches the market.
How the proposed takeover would work
Rather than pursuing a conventional initial public offering, Ellipses intends to enter the stock market through a reverse takeover of Wolfram Resources.
Under the proposed structure, Wolfram would issue new ordinary shares as consideration for acquiring Ellipses.
An additional equity fundraising is also expected to accompany the transaction, although the amount to be raised and the final ownership structure have not yet been disclosed.
A reverse takeover can provide a privately owned company with an alternative route to public markets by combining with an existing listed business.
Sir Chris said the approach would allow Ellipses to broaden its investor base and support the next stage of its development.
"This will drive progress within our portfolio, broaden access to capital and allow our current shareholders to realise growth in the longer term."
Graeme Muir, executive director of Wolfram Resources, welcomed the proposed transaction.
"We are excited to be working with such a strong management team that brings with it years of experience and a proven track record."
Completion targeted for 2027
Both companies will now begin detailed due diligence and negotiations over definitive transaction documents.
The proposed deal is expected to be accompanied by an equity fundraising, although no final financial terms have been agreed.
Ellipses has emphasised that there is no certainty the transaction will proceed.
If completed, the listing would mark a significant development for the company, providing a public market platform as it seeks to advance its oncology pipeline.
For Britain's life sciences sector, the proposed flotation would also represent another opportunity to connect domestic drug development expertise with investment through London's capital markets.
Continue Reading
More News
The Shenzhen summit: three powers, one table and a start

Men dominate finance conference stages as women secure just one third of speaking slots

Majority of Britons believe Brexit has failed, but public divided over whether rejoining EU should be a priority
